News Enbrel unlikely to face Novartis rival until 2018 Amgen arguing that US patent will last until 2029.
News Novartis less exposed to US pricing pressure, says Jimenez Europe and Asia account for a large share of company's income.
News Biogen protects Tecfidera via $1.25bn deal with Forward Biogen could also pay royalties to Forward.
UK & Europe Pfizer's Lyrica patent appeal fails in UK Generics firms free to exploit gap in Pfizer's patent defences.
Oncology ASCO 2026: Chinese firms take a front seat in oncology, with... Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
